GlassScriptPhysician profile
Suresh Mathew
NPI 1922070614
$5,009.87
in general payments reported to CMS, 2019-2025
30 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $333 · 2021: $436 · 2022: $463 · 2023: $864 · 2024: $1,126 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $43.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.98 |
| Education | $43.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $732.05 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $571.81 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $533.82 | 2021-2025 | Terlivaz |
| Amgen INC. | $450.86 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $406.60 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $231.17 | 2021-2025 | |
| Novo Nordisk INC | $198.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $169.97 | 2021-2025 | Benlysta |
| Baxter Healthcare | $166.58 | 2023 | Renal - Pd |
| Travere Therapeutics, INC. | $159.35 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $150.06 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $121.96 | 2019-2023 | Velphoro, Korsuva |
| Mallinckrodt Enterprises LLC | $120.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.79 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $116.36 | 2024-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $99.06 | 2022-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $93.87 | 2020-2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.61 | 2019-2021 | |
| Lilly USA, LLC | $76.42 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $61.47 | 2019-2024 | Vafseo |
| Novartis Pharmaceuticals Corporation | $59.60 | 2019-2024 | |
| Abbvie INC. | $56.82 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $54.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $50.72 | 2022-2023 | Krystexxa |
| Nxstage Medical, INC. | $39.95 | 2024 | |
| Azurity Pharmaceuticals, INC. | $25.33 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $18.37 | 2023 | Verquvo, Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.96 | 2022 | |
| Vantive US Healthcare LLC | $16.68 | 2025 | Renal - Pd |
| Ani Pharmaceuticals, INC. | $15.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.